ANN MOJEIKO: Open Payments
NPI 1801463245 · CLINTON, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,233 in 81 payments from 12 companies in 2025. Trend: 2023 $213 · 2024 $567 · 2025 $1,233
Food & beverage: $1,233
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 29 | $259 |
| Otsuka America Pharmaceutical, Inc. | 14 | $234 |
| Teva Pharmaceuticals USA, Inc. | 9 | $189 |
| Alkermes, Inc. | 6 | $110 |
| ABBVIE INC. | 5 | $109 |
| E.R. Squibb & Sons, L.L.C. | 5 | $86 |
| Lundbeck LLC | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 2 | $35 |
Products named: INGREZZA, REXULTI, ARISTADA, VRAYLAR, ABILIFY ASIMTUFII, AUSTEDO XR, UZEDY, COBENFY.
Industry payments across IA — which companies pay providers there.
